pharmaphorum

AUGUST 11, 2022

The participants undergo monitoring for genetic variations that could potentially negatively impact their reaction to therapies. The program is aiming to genotype roughly 150,000 participants over the next few years to demonstrate the impact personalised testing can have on a large scale. About the Author.

Genome 98

Genome Genomics Drugs Genetics 98

XTalks

SEPTEMBER 28, 2020

The leading global life science company is set to introduce Resolution Bio’s ctDx Lung assay , a non-invasive liquid biopsy test for patients with non-small cell lung cancer (NSCLC). Based on the genetic biomarker(s) identified, the most effective therapy targeting the specific molecular marker can be selected.

Gene 105

Gene DNA Life Science Genotype 105

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Hannelius said this highlights the importance of genetics when developing therapies for type 1 diabetes.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

MARCH 3, 2021

The US Food and Drug Administration (FDA) has granted approval to Nulibry (fosdenopterin) for reducing the risk of death associated with molybdenum cofactor deficiency type A (MoCD Type A), making it the first treatment for the ultra-rare, genetic metabolic disorder. The approval was granted to BridgeBio Pharma, Inc.

FDA Approval 64

FDA Approval Genotype Clinical Trials Clinical Trials 64

XTalks

APRIL 24, 2023

Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. One substantial obstacle is from the additional regulatory requirements of gene therapies containing genetically modified organisms (GMOs). Rare diseases can often be progressive, chronic and fatal.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

The Pharma Data

DECEMBER 9, 2020

The creation of Overland isn’t the only exciting thing happening for international life sciences companies and organizations. Using state-of-the-art genetic approaches and imaging methods, the team has provided a comprehensive insight into defective neuro-glia interactions and their consequences for neurotransmitter homeostasis.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

XTalks

FEBRUARY 4, 2021

Through these collaborations, cohort research dataset sharing programs allow for whole-genome sequence and genotype data to be made available for independent research. Now, if all you’ve already got is a bioresource of 20,000 people that have already been genotyped, you can choose those from that sample and focus your effort.”.

Research 98

Research Biobanking Drugs Genome 98